KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

AbCellera Biologics (ABCL) Non Operating Income (2020 - 2023)

AbCellera Biologics (ABCL) has disclosed Non Operating Income for 4 consecutive years, with $3.1 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Non Operating Income rose 182.19% year-over-year to $3.1 million, compared with a TTM value of $6.8 million through Dec 2023, up 356.3%, and an annual FY2024 reading of $114.4 million, up 1587.88% over the prior year.
  • Non Operating Income was $3.1 million for Q4 2023 at AbCellera Biologics, up from -$11.1 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $16.7 million in Q1 2023 and bottomed at -$11.1 million in Q3 2023.
  • Average Non Operating Income over 4 years is $1.0 million, with a median of -$14000.0 recorded in 2020.
  • Peak annual rise in Non Operating Income hit 2110.94% in 2022, while the deepest fall reached 2423.89% in 2022.
  • Year by year, Non Operating Income stood at -$3.3 million in 2020, then soared by 196.99% to $3.2 million in 2021, then plummeted by 219.7% to -$3.8 million in 2022, then skyrocketed by 182.19% to $3.1 million in 2023.
  • Business Quant data shows Non Operating Income for ABCL at $3.1 million in Q4 2023, -$11.1 million in Q3 2023, and -$2.0 million in Q2 2023.